|
|
|
20 May 2022
EJ Antoni, Research Fellow with Regional Economics in the Center for Data Analysis at The Heritage Foundation, discusses President Biden's student loan "forgiveness" plan, why it is a raw deal for taxpayers, how it is incredibly regressive, drives up tuition costs, and is morally hazardous.
0:00
0:00
Related Podcasts
14 May 2026
Jeremy Nighohossian, Senior Fellow and Economist at the Competitive Enterprise Institute, discusses positive developments in healthcare, including changes in drug development, what the resignation of FDA Commissioner Marty Makary may mean for healthcare policy, and why Certificate of Need (CON) laws impede free market competition and access to care.
30 January 2025
Phil Kerpen, Founder and President of American Commitment, discusses top of the agenda items for the new Trump Administration, how deregulation can drastically improve the lives of Americans and promote economic growth, and why the federal government should be firing and not hiring.
28 June 2024
Lauren Stewart, Senior Federal Legislative Liaison at Americans for Prosperity and Concerned Veterans for America, discusses how President Biden is attempting to rewrite his record on healthcare, how his policies have resulted in limited access and increased costs for Americans, and how a personal option healthcare plan can provide more choices and more solutions.
28 June 2024
Sally Pipes, President and CEO of Pacific Research Institute, discusses how President Biden's price controls will result in prescription drug shortages and discourage innovation, how government mandates and regulations raise insurance costs, and the grim prognosis on Medicare and Medicaid's viability.
28 September 2022
Lindsey Burke, Director of the Center for Education Policy at The Heritage Foundation, discusses President Biden's plan to cancel student debt for some borrowers, the Congressional Budget Office's recent $400 plus billion cost estimate, and why the plan is on shaky legal grounds.
14 February 2020
Timothy Lee, Senior Vice President of Legal and Public Affairs at CFIF, discusses the DOJ's civil antitrust lawsuit seeking to block Sabre Corporation's acquisition of Farelogix, Inc., and why imported price controls for drugs is a prescription for failure.
